Navigation Links
Penwest Pharmaceuticals Announces Intention to Terminate NASDAQ Listing and Registration
Date:10/15/2010

PATTERSON, N.Y., Oct. 15 /PRNewswire-FirstCall/ -- Penwest Pharmaceuticals (Nasdaq: PPCO) ("Penwest") today announces its intention to strike the shares of its common stock from listing and registration on The NASDAQ Stock Market ("NASDAQ"). Penwest intends to take this action in connection with the anticipated merger (the "Merger") of West Acquisition Corp. ("Merger Sub"), an indirect wholly-owned subsidiary of Endo Pharmaceuticals Holdings Inc. ("Endo") (Nasdaq: ENDP), with and into Penwest pursuant to the Agreement and Plan of Merger among Penwest, Merger Sub and Endo, dated August 9, 2010. As previously announced, a special meeting of Penwest shareholders will be held on November 4, 2010 to approve the Merger. Endo and its affiliates own approximately 90.56% of Penwest common stock, and their shares represent sufficient votes to approve the Merger. Penwest intends to consummate the Merger as soon as possible following shareholder approval pursuant to applicable law. Following the completion of the Merger, shares of Penwest common stock will no longer be listed or registered on NASDAQ, or any other stock exchange or quotation system, and upon application to the SEC will be deregistered under the Exchange Act of 1934. Following the completion of the Merger, Penwest will no longer be a public company.

About Penwest

Penwest is a drug development company focused on identifying and developing products that address unmet medical needs, primarily for rare disorders of the nervous system. We are currently developing A0001, or a-tocopherolquinone, a coenzyme Q analog, for inherited mitochondrial respiratory chain diseases. We are also applying our drug delivery technologies and drug formulation expertise to the formulation of product candidates under licensing collaborations. www.penwest.com.


'/>"/>
SOURCE Penwest Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Endo Pharmaceuticals Successfully Completes Tender Offer for Shares of Penwest Pharmaceuticals
2. ISTA Pharmaceuticals Announces Conference Call and Webcast of Third Quarter 2010 Financial Results
3. Isis Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Syndax Pharmaceuticals Announces Issuance of UK Patent for Entinostat
5. Anadys Pharmaceuticals, Inc. Announces Proposed Public Offering of Common Stock
6. Cumberland Pharmaceuticals and Phebra Pty Ltd. Announce the Launch of AcetadoteĀ® in Australia
7. Prolong Pharmaceuticals Secures $30 Million in Funding
8. Amylin Pharmaceuticals to Webcast Third Quarter Results
9. Lexicon Pharmaceuticals to Present at BioCentury Newsmakers in the Biotech Industry Conference Oct. 22nd
10. Titan Pharmaceuticals Announces Journal of the American Medical Association Publication of Phase 3 Probuphineā„¢ Data
11. Cempra Pharmaceuticals Names Richard Kent, M.D., to Its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... , May 27, 2016 ... instances of hypertension is driving ambulatory blood pressure monitoring ... their elasticity and their ability to respond to different ... This condition can lead to various cardiovascular disorders such ... vascular disease. These diseases are growing in prevalence each ...
(Date:5/27/2016)... FRANCISCO , May 27, 2016 ... company focused on developing products for Regenerative Medicine, Neurology and Orphan ... will be presenting at two upcoming investor conferences: ... Center, 730 Third Avenue, New York City , ... 3:00pm Marcum MicroCap Conference   Where: ...
(Date:5/26/2016)... 26, 2016 A key trend ... the emergence of new treatments. Cardax, a development stage ... treatment. The therapy is expected to fulfil large unmet ... is conducting studies to develop new treatments for osteoarthritis. ... genes involved in osteoarthritis are being investigated, and early ...
Breaking Medicine Technology:
(Date:5/27/2016)... ... 27, 2016 , ... Beleza Medspa has initiated a new program ... is the first time that Coolsculpting is being used for for more than just ... ensure they meet the prescribed body-fat standard, measured by the circumference-based tape method. ...
(Date:5/27/2016)... ... May 27, 2016 , ... With ... pharmaceutical, medical and food industries. Aside from its GMP accreditation, Validation Center is ... of successfully certified products, services and staff. , Validation Center is ISO17025 accredited ...
(Date:5/26/2016)... ... May 26, 2016 , ... ... thousands of defective respirators, according to court documents and SEC filings. A ... and Becky Tyler v. American Optical Corporation, Case No. BC588866, Los Angeles County, ...
(Date:5/26/2016)... Washington, D.C. (PRWEB) , ... May 26, 2016 , ... ... the men and women who lost their lives in military battle for the country. ... discount cards in 2015 to provide more programs that empower independence for disabled military ...
(Date:5/26/2016)... ... May 26, 2016 , ... MadgeTech will be showcasing its line of ... Warner, New Hampshire at the MadgeTech headquarters. With products sold in more than 100 ... government agencies, including NASA. , In 2012, NASA strategically set up 17 RHTemp101A ...
Breaking Medicine News(10 mins):